Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOUNCE THERAPEUTICS, INC.

(JNCE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jounce Therapeutics : Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (Form 8-K)

09/15/2021 | 08:22am EDT
Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 13, 2021, the Board of Directors (the 'Board') of Jounce Therapeutics, Inc. (the 'Company'), appointed Jigar Raythatha as a director and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, effective immediately. Mr. Raythatha has been designated as a Class III director to serve in accordance with the Company's Amended and Restated By-Laws until the Company's 2023 Annual Meeting of Stockholders or until his successor has been duly elected and qualified, or until his earlier death, removal or resignation.

Mr. Raythatha served as the president and chief executive officer and a member of the Board of Directors of Constellation Pharmaceuticals, Inc., a public pharmaceutical company, from March 2017 until its acquisition by MorphoSys AG in July 2021. Mr. Raythatha previously served as chief business officer of the Company from December 2012 until February 2017. He earned an M.B.A. from Columbia University and a B.A. in biochemistry and economics from Rutgers University.

In accordance with the Company's non-employee director compensation policy, Mr. Raythatha will receive annual cash compensation of $35,000 as a member of the Board, $6,000 as a member of the Compensation Committee of the Board and $4,000 as a member of the Nominating and Corporate Governance Committee of the Board, as well as reimbursement for reasonable travel and other expenses incurred in connection with attending meetings of the Board and committees thereof. He was granted an option to purchase 31,400 shares of the Company's common stock, par value $0.001 per share, with an exercise price equal to the closing price of the Company's common stock on the Nasdaq Global Select Market on the date of his appointment, which option will vest in equal quarterly installments during the twelve quarters following the grant date, subject to Mr. Raythatha's continued service on the Board. Mr. Raythatha also will enter into a standard form of indemnification agreement with the Company, in the form that is filed as Exhibit 10.12 to the Company's Registration Statement on Form S-1 (File No. 333-215372), filed with the Securities and Exchange Commission on December 30, 2016.

In addition, on September 9, 2021, Cary Pfeffer, a Class III director, notified the Company of his resignation from the Board of Directors, effective as December 31, 2021.

There are no arrangements or understandings between Mr. Raythatha and any other person pursuant to which Mr. Raythatha was elected as a director. There are no transactions in which Mr. Raythatha has an interest requiring disclosure under Item 404(a) of Regulation S-K.




Disclaimer

Jounce Therapeutics Inc. published this content on 15 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2021 12:21:05 UTC.


ę Publicnow 2021
All news about JOUNCE THERAPEUTICS, INC.
10/07JOUNCE THERAPEUTICS : Initiates Enrollment of Phase 1 Trial Cohorts of JTX-8064
MT
10/07JOUNCE THERAPEUTICS : Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monother..
AQ
10/07Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monothe..
CI
09/15JOUNCE THERAPEUTICS : Departures of Directors or Certain Officers; Election of Directors; ..
PU
09/15JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/15Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
GL
09/15Jounce Therapeutics, Inc. Announces Board Changes
CI
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14JOUNCE THERAPEUTICS : Raymond James Upgrades Jounce Therapeutics to Outperform From Market..
MT
09/02Jounce Therapeutics to Present at Upcoming Investor Conferences in September
GL
More news
Analyst Recommendations on JOUNCE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 45,7 M - -
Net income 2021 -69,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,39x
Yield 2021 -
Capitalization 461 M 461 M -
Capi. / Sales 2021 10,1x
Capi. / Sales 2022 24,0x
Nbr of Employees 128
Free-Float 81,7%
Chart JOUNCE THERAPEUTICS, INC.
Duration : Period :
Jounce Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOUNCE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 9,00 $
Average target price 14,50 $
Spread / Average Target 61,1%
EPS Revisions
Managers and Directors
Richard Murray President, Chief Executive Officer & Director
Kimberlee Cobleigh Drapkin Chief Financial Officer & Treasurer
Perry A. Karsen Chairman
Elizabeth G. Trehu Chief Medical Officer
Stephen Farrand Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
JOUNCE THERAPEUTICS, INC.28.57%461
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610